Kornimate/medical-research-clean huggingface dataset:
implant-fixed restorations with ankylos 6.6 mm implants in the edentulous maxilla - a 5-year follow-up study

Conditions: Edentulous Maxilla

Summary: study to assess the performance of six short implants (ankylos c/x 6.6 mm) in the edentulous maxilla supporting fixed full-arch bridges after 5 years in function.

study to assess the performance of six short implants (ankylos c/x 6.6 mm) in the edentulous maxilla supporting fixed full-arch bridges after 5 years in function. the primary objective was to evaluate implant survival.

Eligibility criteria:
inclusion criteria for inclusion in the study subjects had to meet all of the following criteria: 1. aged 18-80 years at inclusion. 2. signed informed consent. 3. in need of full-arch restoration of the maxilla. the following should be considered at inclusion but should be fulfilled at implant placement (visit 3): 4. maxilla: totally edentulous, fulfilling all of the following criteria: 1. history of edentulism: ≥ 6 months and, 2. minimum bone height: ≥ 7 mm and, 3. minimum bone width: ≥ 5.5 mm. 5. mandible: antagonistic natural dentition or tooth/implant borne rehabilitation which can be used to create a stable occlusal fit with the new full-arch restoration of the upper jaw. exclusion criteria any of the following was regarded as a criterion for exclusion from the study: 1. unlikely to be able to comply with study procedures according to investigator's judgement. 2. history of bone augmentation in the maxilla within 6 months prior to surgery. 3. uncontrolled pathologic processes in the oral cavity. 4. bruxism. 5. smoking \>10 cigarettes per day. 6. present alcohol or drug abuse. 7. history of radiation therapy in head and neck region. 8. history of chemotherapy within 5 years prior to surgery. 9. condition that would compromise post-operative tissue healing or osseointegration. 10. bisphosphonates or any other medication that would compromise post-operative healing or osseointegration. 11. known pregnancy at time of inclusion. 12. current or former participation in a clinical study that may interfere with the present study. 13. involvement in the planning and conduct of the study.

Keywords: ankylos simplant maxilla edentulous short implants
ps-omega3 supplementation to attention deficit hyperactivity disorder (adhd) children

Conditions: ADHD

Summary: to assess the effect of phosphatidylserine-omega-3 consumption on the immune system parameters in children suffering from attention and concentration deficits.


Eligibility criteria:
inclusion criteria: 1. parental written informed consent. 2. age: 13≥ years ≥8 (including). 3. gender: both male and female. 4. tova computerized test score ≤-1.8 at baseline. 5. language: subjects, parents, and teachers must be able to read, write and speak hebrew. 6. normal weight and height according to israeli standards. 7. 21 days without any treatment for adhd symptoms, whether medication or food supplement. exclusion criteria: 1. history or current diagnosis of any serious systemic (e.g., diabetes, hyper/hypothyroidism, etc.) or neurological condition (e.g., epilepsy, brain tumors, etc.) 2. pervasive developmental disorder or non-verbal learning disability 3. any evidence of psychotic disorders, suicidal risk, any current psychiatric co-morbidity that required psychiatric pharmacotherapy. 4. history of allergic reactions or sensitivity to marine products (seafood), soy or corn as well as any illness, which may jeopardize the participants health or limit their successful trial completion. 5. having a sibling already included in the study.

Keywords: adhd adhd diagnosed children
the influence of exercise and hydration to the pharmacological response to inhaled terbutalin and salbutamol in men

Conditions: Healthy

Summary: to investigate the effects of dehydration and exercise for the urine secretion of beta2-agonists.

no studies have examined the influence of factors such as exercise and dehydration on the pharmacokinetic profile of asthmatic drugs (beta2-agonists). exercise may modify the metabolism and excretion of drugs, and sweat loss during exercise can result in dehydration, both affecting the urine concentration of the drug.

Eligibility criteria:
inclusion criteria: * men * aerobic capacity more than 50ml / min / kg * more than 5h training pr week exclusion criteria: * smokers * allergy for the medicine * chronic diseases

Keywords: exercise dehydration salbutamol terbutalin
bypass vs. ecmo in lung transplantation (belt)

Conditions: Lung Transplant; Complications

Summary: this study seeks to compare outcomes of 2 different methods of cardiopulmonary support during lung transplant surgeries.

this study will compare use of extracorporeal membrane oxygenation (ecmo) and heart-lung bypass (cpb) during lung transplant procedures and their short and long term outcomes.

Eligibility criteria:
inclusion criteria: 1. the study population will be all patients requiring cardiopulmonary support while undergoing lung transplantation at our institution. exclusion criteria: 1. patients undergoing concomitant cardiac operations with indication for obligate use of cardiopulmonary bypass 2. patient with specific anatomy that require full cardiac decompression such as severe pulmonary hypertension or large heart that are shifted severely into the left chest 3. patients with high likelihood of significant pleural bleeding that will require returning the blood back into the cardiotomy reservoir 4. patients bridged to transplant with ecmo 5. cystic fibrosis/bronchiectasis/resistant infection patients where surgeon will need to remove both lungs prior to implantation 6. patients who the surgeon feels would be better served with cpb rather than ecmo- these patients will be entered into a registry and followed.

Keywords: cardiopulmonary bypass extracorporeal membrane oxygenation primary graft dysfunction hemorrhage mechanical ventilator
slipping rib syndrome: a clinical entity to consider in chest pain

Conditions: Slipping Rib Syndrome

Summary: slipping rib syndrome consists on false or floating ribs hypermobility, whose can force the ribs to come in contact with each other. the authors reported a fourteen case series presenting a slipping rib syndrome.

slipping rib syndrome consists on false or floating ribs hypermobility, whose can force the ribs to come in contact with each other. the authors reported a fourteen case series presenting a slipping rib syndrome. mean age 35.00 ± 10.66 years old; 64.29% men. the 10th rib level was the most predominant, affecting 64.29% of cases. dynamic ultrasound was the gold standard diagnostic tool. different conservative treatments were applied in most of cases.

Eligibility criteria:
inclusion criteria: * patients presenting costal pain around 9th, 10th, or 11th rib. exclusion criteria: * patients younger than 18 years old and older than 80 years old.

Keywords: slipping rib syndrome dynamic ultrasound
does iv ondansetron prevent pruritus after intrathecal morphine in pediatric patients?

Conditions: Pruritus; Nausea/Vomiting

Summary: this is a prospective randomized, double-blind, placebo-controlled study to compare the incidence and intensity of itm-induced pruritus and nausea/vomiting using pre-emptive iv ondansetron, followed by scheduled around the clock (atc) ondansetron vs. our control group, where pruritus and ponv are treated with prn only medications.

pruritus is one of the most common and bothersome side effects of intrathecal morphine (itm) in children, with a reported incidence of 30-60%. clinicians, who have witnessed unbearable itching and scratching in their young patients after intrathecal morphine, may be reluctant to offer this effective pain control to future patients, for fear of these unpleasant sequelae. a study previously found a 40% incidence of pruritus in young children who received intrathecal morphine for major urologic surgery. this is a prospective randomized, double-blind, placebo-controlled study to compare the incidence and intensity of itm-induced pruritus and nausea/vomiting using pre-emptive iv ondansetron, followed by scheduled around the clock (atc) ondansetron vs. control group, where pruritus and ponv are treated with prn only medications. enrollment of 3-17 year olds who are undergoing urologic or orthopedic operative procedures who are scheduled to receive low dose (4-5 mcg/kg) intrathecal morphine for pain management.

Eligibility criteria:
inclusion criteria: * 3-17 years * weight \</= 100kg * scheduled for urologic or orthopedic procedure necessitating intrathecal morphine * ability to use verbal or pictorial pain assessment tools and techniques * informed consent and (if applicable) assent exclusion criteria: * inability to use verbal or pictorial pain scoring scales * hypersensitivity to selective 5-ht receptor antagonists * diagnosed congenital long qt syndrome * severe hepatic impairment * pregnancy or nursing mothers

Keywords: intrathecal morphine
natural killer (nk) cell therapy in locally advanced hcc

Conditions: Locally Advanced Hepatocellular Carcinoma

Summary: this phase 2a trial will evaluate the safety and efficacy of nk cell therapy combined with the hepatic artery infusion chemotherapy (haic) in patients with intermediate and/or locally advanced hepatocellular carcinoma (hcc). we hypothesized that 5-fluorouracil (fu) with immunomodulatory functions would relieve the immunosuppressive microenvironment from the myeloid-derived suppressor cells (mdscs), thereby enhancing the anti-tumor activity of nk cells. thus, the subsequent infusion of autologous nk cells (vax-nk/hcc) following haic treatment may further improve the anti-tumor activity in patients with advanced hcc.

primary objective i. to assess the objective response rate (orr) of administering vax-nk/hcc, autologous nk cells combined with haic in patients with locally advanced hcc. secondary objectives i. to assess the efficacy of administering vax-nk/hcc combined with haic. ii. to assess the safety of administering vax-nk/hcc combined with haic. iii. to assess the immune responses of administering vax-nk/hcc combined with haic. outline: this is a phase 2a study. patients receive haic treatment every 4 week for up to 4 cycles followed by ex-vivo expanded autologous nk cell infusions. the nk cell treatment repeats every 4 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients will be followed until the disease progression.

Eligibility criteria:
inclusion criteria: * subjects with intermediate and/or locally advanced hcc histologically confirmed by biopsy or by typical radiological findings. * subjects who were not suitable for or failed curative treatments such as surgical resection, local ablation therapy, transarterial chemoembolization (tace), sorafenib, atezolizumab, bevacizumab, etc. * child-pugh liver function class a or b. * subjects' ecog performance status of 0 or 1. * the presence of macrovascular invasion. * adequate liver, renal, and hematologic functions. exclusion criteria: * subjects who received the immune cell-based therapy within 6 months before the screening visit. * subjects with a history of a malignancy other than hcc within the last 5 years, liver transplantation, and hypersensitivity to 5-fu or cisplatin. * subjects with extra-hepatic metastases. * subjects who have ongoing autoimmune disease. * female subjects who are pregnant or lactating or women of child-bearing potential but unable to take adequate contraception.
docosahexenoic acid (dha) supplementation and cardiovascular disease in men with high triglycerides

Conditions: Hypertriglyceridemia

Summary: the purpose of this study is to determine the effects of supplementing diets of hyperlipidemic men with dha (docosahexenoic acid) on risk factors for cardiovascular disease. we hypothesize that supplementing diets of hyperlipidemic men with dha will decrease the plasma concentrations of crp (c-reactive protein), inflammatory cytokines, and soluble adhesion molecules. we further hypothesize that dha supplementation will decrease serum triglyceride concentrations and increase hdl concentration.

cardiovascular disease (cvd) and stroke are the leading causes of mortality in the united states, accounting for more than 38% of all deaths. elevated total- and ldl- cholesterol, number of total and small dense ldl particles, triacylglycerols, and low hdl-c are established independent risk factors for the development of cvd. additional novel blood lipid markers used as risk factors for cvd include, increased plasma concentration of remnant like particle-cholesterol (rlp-c), decreased ratio between plasma eicosapentaenoic acid (epa) and arachidonic acd (aa), and decreased omega-3 index (sum of epa and dha as a percentage of total fatty acid content) of the red blood cells. diets rich in omega-3 fatty acids have been shown to be cardio-protective; these diets decreased inflammation, platelet aggregation, cardiac arrhythmias, triglycerides, number of total ldl and small dense ldl particles, and increased omega-3 index, endothelial relaxation and atherosclerotic plaque stability. most of the earlier studies regarding the effects of long chain n-3 pufa on blood lipids were conducted with fish oils which contain a mixture of epa and dha. recently a number of studies have been conducted with epa and dha individually. results from studies with individual fatty acids show that epa and dha have similar effects on some of the lipid parameters, but they are assimilated to a different concentration in tissues and have different effects on lipoprotein particle size, heart rate and blood pressure. the main purpose of this study is to examine the effects of dha supplementation on the above three risk factors.

Eligibility criteria:
inclusion criteria: * fasting serum triglyceride values of 150-400 mg/dl * total cholesterol \< 300 mg/dl * ldl-cholesterol \< 220 mg/dl * bmi between 22 and 35 kg/m2 exclusion criteria: * anti-inflammatory medications including steroids * antihypertensives * non sulfonyl urea medications for diabetes mellitus * drugs that alter serum triacylglycerols and hdl-c levels (i.e. fibrates) * niacin supplements * consumers of illegal substances * consumers of more than 5 drinks of alcohol per week * more than one fish meal per week * dietary supplements of fish oil, flaxseed oil or vitamin c or e

Keywords: docosahexenoic acid (dha) dietary supplement n-3 polyunsaturated fatty acid cardiovascular disease
human cell line-derived recombinant factor viii (human-cl-rhfviii) in previously untreated patients

Conditions: Severe Hemophilia A

Summary: investigate the inhibitor development rate of human cl rhfviii in previously untreated patients with severe hemophilia a.


Eligibility criteria:
inclusion criteria: * male patients * severe hemophilia a (fviii:c \<1%) * no previous treatment with fviii concentrates or other blood products containing fviii exclusion criteria: * diagnosis with a coagulation disorder other than hemophilia a * severe liver or kidney disease * concomitant treatment with any systemic immunosuppressive drug

Keywords: previously untreated patients
simpliciti ide trial; replacing the humeral head in total shoulder arthroplasty

Conditions: Primary Generalized (Osteo)Arthritis; Post-traumatic Arthrosis of Other Joints, Upper Arm

Summary: the purpose of this study is to demonstrate safety and efficacy of the simpliciti shoulder system in total shoulder arthroplasty.


Eligibility criteria:
inclusion criteria: * adult subject 22 years or older * clinical indication for total shoulder replacement due to primary diagnosis of arthritis. primary arthritis for this study includes osteoarthritis, and/or traumatic arthritis. * scapula and proximal humerus must have reached skeletal maturity * subject with a constant score ≥ 20 * willing and able to comply with the protocol * willing and able to sign the informed consent (or the legally authorized representative will sign for the subject) exclusion criteria: * lack of sufficient sound bone to seat and support the implant such as: 1. rapid joint destruction, marked bone loss or bone resorption; 2. destruction of the proximal humerus that precludes rigid fixation of the humeral component; and 3. osteomalacia * metal allergies or sensitivity, including a known allergic reaction to implant metals (e.g., nickel) or polyethylene * infection at or near the site of implantation, including: 1. glenohumeral joint infection 2. osteomyelitis * distant or systemic infection * medical conditions or balance impairments that could lead to falls * prior open shoulder surgery on the shoulder to be treated in the study including failed rotator cuff surgery, but excluding successful shoulder arthroscopy * any full thickness rotator cuff tear at the time of surgery or a nonfunctional rotator cuff * excessive glenoid bone loss defined by preoperative computed tomography (ct) scans of the shoulder which show insufficient glenoid bone, or insufficient bone identified at the time of surgery * metabolic disorders which may impair bone function * nonfunctional deltoid muscle * neuromuscular compromise condition of the shoulder (e.g., neuropathic joints or brachioplexus injury with a flail shoulder joint) * known active metastatic or neoplastic diseases, paget's disease or charcot's disease * currently, or within the last 6 months, or planning to be on chemotherapy or radiation * currently taking \> 5mg/day corticosteroids (e.g. prednisone) excluding inhalers, within 3 months prior to surgery * female subjects who are pregnant or planning to become pregnant within the study period * in the surgeon's opinion, the subject is unable to understand the study or be compliant with the follow up or have a history of non-compliance with medical advice * history of any cognitive or mental health status that would interfere with study participation * alcohol or drug abuse * engages in manual labor or sports activities that could affect shoulder outcome * currently enrolled in any clinical research study that might interfere with the current study endpoints
medical yoga for patients with stress-related symptoms

Conditions: Stress-related Illness/Anxiety

Summary: the purpose of this study is to compare the effect of medical yoga as a group treatment, to conventional treatment provided by a physical therapist, for people with perceived stress-related symptoms. forty people are to be randomized to either: 1. intervention group - medical yoga, group treatment for eight weeks, 60 minutes per week, with the guidance of a physical therapist. or 2. control - treatment as usual (tau) in physical therapy.


Eligibility criteria:
inclusion criteria: * perceived stress and anxiety, which could be expressed as for example as tension in the neck and shoulders, insomnia, anxiety and headaches. exclusion criteria: * do not understand swedish (as group instructions need to be understood), * pregnancy, * psychotic symptoms, * ongoing or physical therapy treatment the last three months, * previously participated in medical yoga group.
estimating jaw, neck, and shoulder range of motion using an ai model

Conditions: Oral Cancer

Summary: this observational study aims to develop an ai-based system for tracking mandibular and shoulder movements using deep learning techniques. it will compare ai-generated pose estimations with gold standard measurements to assess accuracy, particularly in patients with functional impairments from oral cancer treatment, such as trismus, spinal accessory nerve dysfunction, neck dystonia, and radiation fibrosis.

due to the involvement of various structures, patients with oral cancer may experience functional impairments after treatment, such as trismus, spinal accessory nerve dysfunction, neck dystonia, radiation fibrosis, and fatigue. this observational study aims to develop an ai-based system for tracking mandibular and shoulder movements using deep learning techniques. ai-generated pose estimations will be compared with gold standard measurements: maximal mouth opening will be compared with caliper measurements, and therabilte scale, while shoulder abduction range of motion will be compared with universal goniometer measurements. we will recruit 20 healthy adults and 20 oral cancer patients. data on maximal mouth opening and shoulder abduction will be collected through video recordings, calipers, therabilte scale, and universal goniometers. the videos will be analyzed using deep learning to estimate mouth opening and shoulder abduction angles. these estimates will then be compared with the gold standard measurements. the intraclass correlation coefficient (icc), mean absolute error (mae), and coefficient of variation (cv) will be used as performance indicators to assess and compare the reliability, accuracy, and consistency of the models.

Eligibility criteria:
inclusion criteria: * healthy adults without a history of head, neck or shoulder injury or surgery, and without hnc-related radiotherapy or chemoradiotherapy * oral cancer patients with trismus, clinical signs of neck or shoulder joint impairment after oral cancer surgery or radiotherapy * age between 20 and 65 years exclusion criteria: * could not communicate * had any disorder that could influence movement performance

Keywords: oral cancer shoulder range of motion artificial intelligence pose estimation maximal mouth opening
act for healthy living: a brief acceptance and commitment therapy intervention for women with obesity

Conditions: Obesity

Summary: the goal of this clinical trial is to investigate if a 4-hour acceptance and commitment therapy workshop can help the adoption and maintenance of healthy lifestyle behaviors in women with obesity. the objectives are as follows: 1. to assess changes in act-related constructs before and after the workshop 2. to assess changes in other psychological constructs that have been shown to hinder successful weight management before and after the workshop 3. to assess changes in dietary and physical activity behaviors before and after the workshop. participants will complete baseline questionnaires and anthropometric measures at three time points: baseline, 1 week after the workshop, and 1 month after the workshop. researchers will compare an active intervention group to a waitlist control group to investigate the efficacy of the workshop.

acceptance and commitment therapy interventions demonstrate efficacy for weight loss. act-based workshops represent an innovative and potentially scalable application of this approach to obesity treatment. 70 women will be recruited to participate. half of the participants (n = 35) will receive a brief ( approximately 4-hour) workshop that aims to facilitate the development and maintenance of healthy lifestyle behaviors using act principles such as valued living and committed action. outcomes will be assessed at baseline, 1-week, and 1-month post-intervention.

Eligibility criteria:
inclusion criteria: * inclusion criteria will be individuals who self-identify as women, have a bmi of \>30.0 kg/m2 based on self-reported height and weight, are able to read and understand written and spoken english, and have a primary residence within 50 miles driving distance of the university of alabama at birmingham campus. exclusion criteria: * exclusion criteria will include presence of eating disorder symptoms (assessed by participant self-report for a former or current diagnosis) presence of a major mood disorder (assessed by participant self-report of a current or former diagnosis), recent weight change of +/-10 pounds, recent use of prescription medication for weight loss, and current participation in another weight management program.